




The relative strengths and weaknesses of Anebulo Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Anebulo Pharmaceuticals Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 147% points. The greatest weakness of Anebulo Pharmaceuticals Inc is the variable Net Income, reducing the Economic Capital Ratio by 58% points.

The company's Economic Capital Ratio, given in the ranking table, is 288%, being 75% points above the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	11,670
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	535
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	534
Other Net Income	51
Other Revenues	0
Property and Equipment	0
Research and Development	5,600
Selling, General and Administrative Expense	6,183

Output Variable	Value in 1000 USD
Assets	11,670
Liabilities	1,069
Expenses	11,784
Revenues	0
Stockholders Equity	10,601
Net Income	-11,732
Comprehensive Net Income	-11,732
BaseVar	12,287
ECR before LimitedLiability	179%
Economic Capital Ratio	288%